Calpol Six Plus Suspension Sugar Free
Out of date information, search anotherSUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Calpol Six Plus Suspension Sugar Free
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Calpol Six Plus Suspension Sugar Free contains 250 mg Paracetamol in each 5 ml.
3 PHARMACEUTICAL FORM
Suspension.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Calpol Six Plus Suspension Sugar Free is indicated for the treatment of mild to moderate pain and as an antipyretic. It can be used in many conditions including headache, toothache, earache, sore throat, colds and influenza, aches and pains and post-immunisation fever.
4.2 Posology and method of administration
4.2.1 Posology Children aged 6 to 12 years:
|
Child’s Age |
How Much |
How often (in 24 hours)* |
|
Under 6 years |
Not recommended |
N/A |
|
6 - 8 years |
5 ml |
4 times |
|
8 - 10 years |
7.5 ml (5ml + 2.5 ml) |
4 times |
|
10 - 12 years |
10 ml (5ml+5ml) |
4 times |
• Do not give more than 4 doses in any 24 hour period
• Leave at least 4 hours between doses
• Do not give this medicine to your child for more than 3 days
without speaking to your doctor or pharmacist_
Children aged 12-16 years: 10 - 15 ml (Two to three 5 ml doses) up to 4 times a day
Adults and children over 16 years: 10 - 20 ml (Two to four 5 ml doses) up to 4 times a day.
It is important to shake the bottle for at least 10 seconds before use.
The Elderly:
In the elderly, the rate and extent of paracetamol absorption is normal but plasma half-life is longer and paracetamol clearance is lower than in young adults.
4.3 Contraindications
Calpol Six Plus Suspension Sugar Free is contra-indicated in patients with known hypersensitivity to paracetamol, or any of the other components.
4.4 Special warnings and precautions for use
Calpol Six Plus Suspension Sugar Free should be used with caution in severe renal impairment or severe hepatic impairment. The hazards of overdose are greater in those with non-cirrhotic alcoholic liver disease.
Sorbitol and maltitol may have a mild laxative effect. Each 5 ml of this product contains 1.935 g sorbitol and 2.04g of maltitol.
Calorific values: 2.6 kcal/g sorbitol and 2.3 kcal/g maltitol.
The label contains the following statements:
Contains paracetamol.
Do not give this medicine with any other paracetamol containing products.
For oral use only.
Never give more medicine than shown in the table.
Always use the syringe supplied with the pack.
Do not give more than 4 doses in any 24 hour period.
Leave at least 4 hours between doses.
Do not give this medicine to your child for more than 3 days without speaking to your doctor or pharmacist
As with all medicines, if your child is currently taking any other medicine consult your doctor or pharmacist before using this product.
Keep out of the reach and sight of children.
Do not store above 25°C. Store in the original package.
Shake the bottle for at least 10 seconds before use.
Do not exceed the stated dose.
If symptoms persist consult your doctor.
Immediate medical advice should be sought in the event of an overdose, even if the child seems well. (label)
Immediate medical advice should be sought in the event of an overdose, even if the child seems well, because of the risk of delayed, serious liver damage.
(leaflet)
If the child needs more than the doses shown in the table, or if fever doesn’t go away within 3 days speak to your doctor straight away. (leaflet)
4.5 Interaction with other medicinal products and other forms of interaction
The speed of absorption of paracetamol may be increased by metoclopramide or domperidone and absorption reduced by colestyramine.
The anticoagulant effect of warfarin and other coumarins may be enhanced by prolonged regular use of paracetamol with increased risk of bleeding; occasional doses have no significant effect.
Chronic alcohol intake can increase the hepatotoxicity of paracetamol overdose and may have contributed to the acute pancreatitis reported in one patient who had taken an overdose of paracetamol. Acute alcohol intake may diminish an individual’s ability to metabolise large doses of paracetamol, the plasma half-life of which can be prolonged.
The use of drugs that induce hepatic microsomal enzymes, such as anticonvulsants and oral contraceptives, may increase the extent of metabolism of paracetamol, resulting in reduced plasma concentrations of the drug and a faster elimination rate.
4.6 Fertility, pregnancy and lactation
Epidemiological studies in human pregnancy have shown no ill effects due to paracetamol used in the recommended dosage, but patients should follow the advice of the doctor regarding its use.
Paracetamol is excreted in breast milk but not in a clinically significant amount. Available published data do not contraindicate breast feeding.
4.7 Effects on ability to drive and use machines
None known.
4.8 Undesirable effects
Adverse effects of paracetamol are rare. Very rarely hypersensitivity and anaphylactic reactions including skin rash may occur.
There have been reports of blood dyscrasias including thrombocytopenia and agranulocystosis but these were not necessarily causally related to paracetamol.
Chronic hepatic necrosis has been reported in a patient who took daily therapeutic doses of paracetamol for about a year and liver damage has been reported after daily ingestion of excessive amounts for shorter periods. A review of a group of patients with chronic active hepatitis failed to reveal differences in the abnormalities of liver function in those who were long-term users of paracetamol nor was the control of the disease improved after paracetamol withdrawal.
Nephrotoxicity following therapeutic doses of paracetamol is uncommon. Papillary necrosis has been reported after prolonged administration.
4.9 Overdose
Immediate treatment is essential in the management of paracetamol overdose. Despite a lack of significant early symptoms, patients should be referred to hospital urgently for immediate medical attention and any patient who had ingested around 7.5 g or more of paracetamol in the preceding 4 hours should undergo gastric lavage.
Administration of oral methionine or intravenous N-acetylcysteine which may have beneficial effect up to at least 48 hours after overdose, may be required. General supportive measures must be available
Symptoms of paracetamol overdosage in the first 24 hours are pallor, nausea, vomiting, anorexia, and abdominal pain. Liver damage may become apparent 12 to 48 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, hepatic failure may progress to encephalopathy, coma and death. Acute renal failure with acute tubular necrosis may develop even in the absence of severe liver damage. Cardiac arrhythmias and pancreatitis have been reported.
Liver damage is possible in adults who have taken 10 g or more of paracetamol.
5 PHARMACOLOGICAL PROPERTIES
Pharmacodynamic properties
5.1
Paracetamol has analgesic and antipyretic effects similar to those of aspirin and is useful in the treatment of mild to moderate pain. It has weak antiinflammatory effects.
5.2 Pharmacokinetic properties
Paracetamol is rapidly and almost completely absorbed from the gastrointestinal tract. Peak plasma concentrations are reached 30-90 minutes post dose and the plasma half-life is in the range of 1 to 3 hours after therapeutic doses. Drug is widely distributed throughout most body fluids. Following therapeutic doses 90-100% of the drug is recovered in the urine within 24 hours almost entirely following hepatic conjugation with glucuronic acid (about 60%), sulphuric acid (about 35%) or cysteine (about 3%). Small amounts of hydroxylated and deacetylated metabolites have also been detected. Children have less capacity for glucuronidation of the drug than do adults. In overdosage there is increased N-hydroxylation followed by glutathione conjugation. When the latter is exhausted, reaction with hepatic proteins is increased leading to necrosis.
5.3 Preclinical safety data
The active constituent of this product is a well known constituent of medicinal products and its safety profile is well documented.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Maltitol Liquid (E965)
Sorbitol Liquid (70% non crystallising) (E420) Glycerol
Dispersible cellulose Xanthan gum
Methyl parahydroxybenzoate (E218)
Propyl parahydroxybenzoate (E216) Acesulfame potassium Polysorbate 80 Saccharin Sodium Strawberry flavour 500286E Strawberry Cream 11407-33 Purified water
6.2 Incompatibilities
None known
6.3 Shelf life
36 months for the bottles.
6.4 Special precautions for storage
Do not store above 25°C. Store in the original package.
6.5 Nature and contents of container
Amber glass bottle closed with a two-piece plastic child resistant, tamper evident closure fitted with a polyethylene or polyvinylidene chloride (PVDC) laminate faced wad.
Or
Amber glass bottle with a two-piece white plastic child-resistant external cap, fitted with an inner plastic cap, including a tamper evident ring, in high density polyethylene. The cap contains a plug made of Low Density Polyethylene (LDPE).
Pack size: 80 ml. A syringe with a 2.5 ml and 5ml measure is supplied with this product.
6.6 Special precautions for disposal
No special requirements.
7 MARKETING AUTHORISATION HOLDER
McNeil Products Limited
Foundation Park
Roxborough Way
Maidenhead
Berkshire
SL6 3UG
UK
8 MARKETING AUTHORISATION NUMBER(S)
PL 15513/0164
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
29 October 2008
10 DATE OF REVISION OF THE TEXT
29/06/2012